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Abstract
Objectives. SLE is a systemic autoimmune disease with an annual incidence of 3.8 per 100 000. Several
pathogenic mechanisms are believed to be operating in SLE, including an impaired clearance of apoptotic
cells, activation of the type I IFN pathway and generation of autoimmune leucocytes. Growth
arrest-specific protein 6 (Gas6) and its receptor Axl are known to regulate inflammation and may be
implicated in lupus pathogenesis. We have recently developed immunological methods to quantify the
vitamin-K-dependent protein Gas6 and its soluble receptor sAxl in human plasma, which we have used to
investigate the role of Gas6 and soluble Axl in SLE.
Methods. We have investigated the relation between the plasma concentrations of Gas6 and sAxl and
disease activity and specific symptoms in 96 SLE patients.
Results. Gas6 and sAxl concentrations correlated with SLEDAI (r=0.48, P<0.001 and r=0.39, P<0.001,
respectively). Furthermore, concentrations of Gas6 and sAxl correlated with ESR and CRP and inversely
with haemoglobin levels. Gas6 and sAxl concentrations were significantly higher in patients with anti-DNA
antibodies, leucopenia and GN.
Conclusion. The plasma concentrations of Gas6 and sAxl vary with disease activity in SLE, in particular
GN, and may have a role in lupus pathogenesis. Furthermore, Gas6 and sAxl may be of use as biomarkers
of disease activity.
Key words: Systemic lupus erythematosus, Growth arrest-specific protein 6, Axl, Receptor tyrosine kinase,
Vitamin K, Inflammation, Autoimmunity.
Introduction
SLE is a systemic autoimmune disease with complex clin-
ical manifestations affecting 27.7 of 100 000 of the popu-
lation, according to a study performed in Birmingham, UK:
a large city with a broad ethnic mix [1]. The disease is
characterized by the presence of ANAs [2], deficient clear-
ance of apoptotic debris [3] and over-activation of the
type I IFN genes [4]. Peripheral blood mononuclear cells
from SLE patients have an increased expression of
IFN-regulated genes [5].
It has been shown that pre-incubation with Growth
arrest-specific protein 6 (Gas6) can decrease the secre-
tion of pro-inflammatory cytokines of dendritic cells [6].
Gas6 up-regulates suppressor of cytokine signalling-1
(SOCS1), decreasing the response to inflammatory stimuli
[7], implicating Gas6 as a potential regulator of SLE
pathogenesis.
Gas6 was originally found as a protein produced by
growth arrested fibroblasts [8]. It is structurally related to
the anticoagulant protein S, sharing its domain organiza-
tion and 44% of amino acid identity. While protein S has
been shown to be an important regulator of the coagula-
tion cascade, Gas6 has not, so far, been shown to influ-
ence coagulation in humans. However, according to
studies of Gas6
/ mice, Gas6 is suggested to stimulate
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Gas6 has been found to be present in human circulation
at low levels (0.160.28nM) [10]. It reacts as an
acute-phase reactant and is increased during sepsis [11,
12] and pancreatitis [13].
Gas6 binds to the Axl tyrosine kinase receptor [14],
which results in activation of the PI3K [15] and ERK
kinase pathways and increased proliferation and survival
[16]. The Axl receptor tyrosine kinase was originally found
as an over-expressed gene in leukaemia cells, but is
expressed in a wide variety of cells [17]. High Axl expres-
sion is a marker of negative prognosis for glioma [18] and
kidney cancer [19].
We have recently shown that a soluble form of Axl, con-
sisting of the extracellular part of the protein, is present in
normal human serum at sub-nanomolar concentrations
(0.30.9nM) [20]. The soluble Axl (sAxl) is bound to Gas6
in serum, which suggests circulating Gas6 to be inactive
because sAxl binding to Gas6 has been shown to inhibit
Gas6-mediated activation of cell-bound receptors in vitro
[21] and in vivo [22]. In this study, we show that Gas6 and
sAxl concentrations correlate to disease activity in SLE,
particularly in cases with lupus nephritis, indicating that
both Gas6 and Axl may have a role in the disease.
Materials and methods
Patients
The 96 SLE patients included in the study were recruited
from 1985 to 2005 at the Department of Rheumatology,
Lund University, Lund, Sweden. There were 11 men and
85 women in the study, all fulfilling four or more ACR clas-
sification criteria [23]. The mean disease duration at the
time of the study was 10 years and the mean age at SLE
diagnosis was 35 years. Disease activity was evaluated
using SLEDAI-2K [24], and DNA antibodies were detected
with Crithidia luciliae IF test. EDTA plasma were collected
and stored in aliquots at 80C until tested.
Evaluation time points were selected with the objective
of including a wide range of manifestations and SLEDAI
scores, also including nine patients without evidence
of active disease. The ACR criteria fulfilled are summar-
ized in Table 1. The different manifestations of disease
that were present at the time of blood sampling are
summarized in Table 2. The mean SLEDAI score was
8.7 (range 032). Out of the 96 patients, 69 were treated
with glucocorticoids, 49 were treated with anti-malarial
drugs, 20 with AZA, 13 with warfarin, 5 with ciclosporin,
3 with CYC, 3 with immunoglobulin, 2 with MMF and
1 with tacrolimus. As warfarin affects Gas6, we con-
sidered the possibility of excluding warfarin-treated pa-
tients from the study. However, the warfarin-treated
patients did not have SLEDAI scores significantly different
from the other treated patients, and the correlations re-
ported were valid even when excluding the warfarin-
treated patients. Therefore, these patients were included
in the study. All the patients gave written consent to the
study, which was approved by the Regional Ethical
Review Board in Lund.
ELISAs
The ELISAs for Gas6 [10] and sAxl [20] have been
described earlier. In short, maxisorp plates (Dako,
Glostrup, Denmark) were coated with a polyclonal anti-
body to respective antigen before blocking with 3% fish
gelatin in 50mM Tris, 150mM NaCl, pH 7.5 [Tris-buffered
TABLE 2 Clinical manifestations as defined by SLEDAI
scoring system at time point of active disease
SLEDAI manifestation Positive, % (n=96)
Seizure 1
Visual 4
Cranial neuropathy 1
Lupus headache 1
Cerebrovascular insult 3
Vasculitis 14
Arthritis 24
Myositis 2
Cylinderuria 17
Haemoglobinuria 20
Proteinuria 23
Pyuria 0
Rash 34
Alopecia 8
Oral ulcers 4
Pleuritis 7
Pericarditis 5
Complement 45
Anti-DNA antibodies 33
Fever 11
Thrombocytopenia 6
Leucopenia 17
Other 0
TABLE 1 Demographic data and distribution of ACR
classification criteria for the patients involved in the
study (n=96)
Patient demographics
Number of female patients 85
Number of male patients 11
Age at diagnosis, mean, years 35
Age range, years 1485
Mean years affected 10
Criteria Positive, % (n=96)
Malar rash 57
Discoid LE 31
Photosensitivity 67
Oral ulcers 29
Arthritis 75
Serositis 54
GN 24
Seizures, psychosis 10
Haematology 52
Immunology 71
ANA 100
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washed 5-fold with TBS with 0.1% Tween 20 between
every step. The plasma samples were diluted 10-fold in
the blocking buffer but with the addition of 10% rabbit
serum to minimize problems with autoreactive antibodies
in the samples. The standard curves were made by serial
dilution of known amounts of recombinant protein and
negative controls by using buffer alone. Biotinylated
rabbit antibodies were used to detect the proteins to-
gether with avidin-biotinylated enzyme complex/horse-
radish peroxidase (ABC/HRP) complexes (Dako). The
signals were visualized with ortophenylenediamine and
hydrogen peroxide before stopping the colour reaction
with addition of 1M sulphuric acid. The absorbance was
determined in an automated plate reader at 490nm.
Statistics
SPSS 17 (IBM, New York, NY, USA) was used for the
multivariate analyses [analysis of variance (ANOVA) and
multiple regression] and Graphpad 4.0 (Graphpad
Software, La Jolla, CA, USA) was used for all other
statistical analysis. Correlations were evaluated with
Spearman’s rank correlation test. Comparisons between
groups were performed using the MannWhitney U-test.
When comparing pairs of samples, the Wilcoxon signed
rank test was used. As there is no consensual way to
correct for multiple testing with dependent variables,
P<0.01 was considered statistically significant to
reduce the risk of accepting false hypotheses. The results
of the initial exploratory analysis using this significance
level (Tables 3 and 4) were further analysed by multivariate
analyses, using methods mentioned above.
Results
All patients with low SLEDAI score (<3) had Gas6 concen-
tration below the upper normal level, and 18 of 20 patients
with low SLEDAI had sAxl within the normal range deter-
mined in healthy controls, as described [10, 20]. However,
we noticed a statistically significant correlation between
SLEDAI score and concentrations of Gas6 (P<0.0001,
r=0.48, n=96) and sAxl (P=0.0001, r=0.39, n=94)
(Fig. 1A and B).
Gas6 and sAxl correlated strongly to each other
(r=0.57) and both were positively correlating to sedimen-
tation rate (r=0.44 and r=0.48) and CRP (r=0.30 and
r=0.32), and inversely to haemoglobin (r=0.48 and
r=0.51). Gas6 correlated inversely with leucocyte
count (r=0.39). There was a trend of a negative correl-
ation between Gas6 and C3—and a similar trend for
sAxl—but there were no correlations to creatinine clear-
ance, C4, C1q or age (Table 3). The parameters giving
the significant correlations of Table 3 were subjected
to multiple regression analysis. When Gas6 was used as
dependent variable, sAxl was the only highly significant
independent variable (P<0.0003).
In 45 patients, samples from two time points, one with
higher and one with lower disease activity, were available.
Median and range of SLEDAI was 10 (332) and 0 (012) in
the high and low SLEDAI group, respectively. The mean
Gas6 concentration was 0.21nM for the high SLEDAI
group as compared with 0.16nM for low SLEDAI group
(P=0.0003, n=45). For sAxl, the corresponding concen-
trations were 0.92 and 0.81nM, respectively (P=0.027,
n=42) (Fig. 2A and B).
We evaluated the correlation between Gas6 and sAxl
concentrations and active SLE manifestations. High
Gas6 and sAxl were observed in the 24 patients with
GN (P<0.001 for both, Fig. 3A and B); in 21 patients, a
biopsy was taken and in 18 of the patients, World Health
Organization classes 3 or 4 were found. High Gas6 was
also observed when anti-DNA antibodies, leucopenia or
rash was present, and there was a trend of higher Gas6 in
patients with vasculitis. Higher sAxl concentrations could
be observed when anti-DNA antibodies or leucopenia was
present. There was a trend to higher sAxl in patients with
serositis and vasculitis and lower sAxl in patients with
arthritis (Table 4). The significant variables in Table 4
were analysed with ANOVA. In the ANOVA analysis of
Gas6, GN (P=0.0013) and leucopenia (P=0.0059) were
the only independent factors. In the sAxl ANOVA analysis,
only GN remained independent (P=0.0009).
Discussion
We have determined the Gas6 and sAxl concentrations in
a number of SLE patients in relation to disease phenotype
TABLE 3 Correlations between Gas6 and sAxl
concentrations and biochemical analytes and age
Parameter Spearman’s rP -value
Gas6 correlations
SLEDAI 0.48 <0.0001
Haemoglobin 0.48 <0.0001
Leucocytes 0.39 <0.0001
Thrombocytes 0.07 0.4867
Creatinine 0.03 0.7838
Sedimentation rate 0.44 <0.0001
CRP 0.30 0.0038
C1q 0.13 0.2150
C3 0.26 0.0110
C4 0.07 0.4828
Age 0.09 0.3576
sAxl 0.57 <0.0001
sAxl correlations
SLEDAI 0.39 <0.0001
Haemoglobin 0.51 <0.0001
Leucocytes 0.15 0.1419
Thrombocytes 0.09 0.3814
Creatinine 0.00 0.9772
Sedimentation rate 0.48 <0.0001
CRP 0.32 0.0025
C1q 0.12 0.2473
C3 0.20 0.0555
C4 0.03 0.7651
Age 0.18 0.0849
The correlations were estimated using the Spearman’s rank
correlation test. The highly significant correlations (SLEDAI,
haemoglobin, leucocytes, sedimentation rate, CRP and sAxl)
were analysed by multiple regression.
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disease activity measured by SLEDAI-2K and increase
during periods of higher disease intensity. Gas6 and sAxl
correlate with sedimentation rate and CRP, indicating a
role linked to inflammation. Gas6 and sAxl plasma concen-
trations are higher in patients with active GN, but Gas6 or
sAxldidnotcorrelatetocreatinin,C1qorC4.Recently,Suh
et al. [25] reported on a study in which Gas6 was measured
in patients with SLE. In agreement with our results, they
found the concentrations of Gas6 in SLE patients to be
similar to those of controls. They found slightly higher
Gas6 levels in a small number of patients with neurological
disease but apart from that found no association between
disease activity and Gas6 levels. Our study includes twice
as many patients as that of Suh et al. [25] and contains
patients with a wide variation in symptoms, which may
contribute explanation to the difference in results.
Interestingly, Gas6 and Axl have been implicated to be
important in experimental GN (Gas6
/ mice are pro-
tected) [22], as well as diabetic and nephrotoxic nephritis
[26, 27]. Whether Gas6 has a role in the pathogenesis
of SLE-associated GN remains to be determined. Gas6
signalling can have several effects, related to both the
initiation of inflammation and the regulation of established
inflammation. Gas6 has been shown to decrease the
levels of secreted cytokines by dendritic cells [7], and war-
farin treatment or Axl-Fc can decrease the symptoms of
GN in mice [22].
FIG.1Correlation of the SLEDAI with Gas6 and sAxl concentrations in plasma. Each symbol represents one person.
(A) The correlation between SLEDAI and Gas6 (r=0.48, P<0.0001, n=96). (B) The correlation between SLEDAI and
sAxl (r=0.39, P=0.0001, n=94). The correlations were evaluated with Spearman’s non-parametric test.
TABLE 4 Gas6 and sAxl concentrations in patients in relation to manifestations seen in SLE
Symptom Positive, n Negative, median (range) Positive, median (range) P-value
n=96 Gas6, nM
Anti-DNA antibodies 31 0.16 (0.090.43) 0.22 (0.070.47) 0.0004
Arthritis 23 0.17 (0.090.43) 0.16 (0.070.47) 0.2055
Fever 11 0.17 (0.070.47) 0.22 (0.120.31) 0.3033
GN 24 0.16 (0.070.47) 0.26 (0.090.37) <0.0001
Leucopenia 16 0.16 (0.070.43) 0.27 (0.130.47) 0.0003
Rash 33 0.16 (0.070.47) 0.19 (0.110.37) 0.0068
Serositis 9 0.17 (0.070.47) 0.18 (0.120.31) 0.5631
Thrombocytopenia 6 0.17 (0.070.43) 0.16 (0.130.47) 0.8145
Vasculitis 15 0.17 (0.090.47) 0.23 (0.070.34) 0.0406
n=94 sAxl (nM)
Anti-DNA antibodies 30 0.72 (0.382.34) 0.97 (0.533.01) 0.0004
Arthritis 22 0.82 (0.383.01) 0.67 (0.442.34) 0.0495
Fever 9 0.74 (0.383.01) 0.83 (0.471.18) 0.4959
GN 24 0.68 (0.382.34) 1.12 (0.603.01) <0.0001
Leucopenia 15 0.73 (0.383.01) 0.94 (0.631.59) 0.0025
Rash 31 0.73 (0.383.01) 0.82 (0.552.02) 0.2552
Serositis 9 0.74 (0.383.01) 0.98 (0.551.50) 0.0516
Thrombocytopenia 6 0.75 (0.383.01) 0.78 (0.611.15) 0.7278
Vasculitis 14 0.74 (0.383.01) 0.99 (0.452.02) 0.0501
Differences in Gas6 and sAxl levels were evaluated with the MannWhitney U-test. The highly significant variables were
analysed further with ANOVA.
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Gas6 and sAxl correlate with SLEDAIIn conclusion, this study suggests that both Gas6 and
sAxl concentrations correlate with the SLE disease activity
and are increased in patients with anti-DNA antibodies,
leucopenia and GN. Gas6 and sAxl may be useful add-
itions to the panel of biomarkers of SLE disease activity.
Rheumatology key messages
. Plasma Gas6 and sAxl correlate with SLEDAI score
in SLE patients.
. Gas6 and sAxl are increased during GN and when
anti-DNA antibodies are present.
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